Skip to Main Content
An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Updates in lethal prostate cancer in the PLCO trial

Principal Investigator

Name
Jonathan Shoag

Degrees
MD

Institution
Weill Cornell Medicine

Position Title
Assistant professor

Email
jonathan.shoag@uhhospitals.org

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
PLCO-701

Initial CDAS Request Approval
Dec 21, 2020

Title
Updates in lethal prostate cancer in the PLCO trial

Summary
Survival characteristics of patients in the PLCO trial were well described at the time of initial data publication. Prostate cancer is distinct from lung, colorectal, and ovarian malignancies, however, in that the tumors generally progress slowly and several years can lapse between diagnosis and death. As a consequence, mortality data is more likely to evolve significantly over time and impact results of previously published studies. We hope to utilize updated survival data from patients enrolled in the PLCO trial to shed light on lethal prostate cancer in the screening arm of the PLCO trial. We plan to analyze demographic and oncologic data amongst patients in the screening arm in relation to prostate cancer mortality. A granular understanding of this cohort of patients better informs the underpinnings of why cancer screenings fail, and is important in the interpretation of the trial's various conclusions. We anticipate that updated survival data on these cohorts will strengthen previous findings and have the potential to reveal novel predictors of cancer-specific mortality.

Aims

-understand patterns of lethal prostate cancer in screened patients
-identify predictors and pre-disposing factors leading to death from prostate cancer in a screened population
-strengthen the conclusions of initial reports describing this unique cohort

Collaborators

N/a